Evidence map›Paper›PMID 41640710›Full record

ArticleWorld journal of radiology2026

Radiotherapy combined with bevacizumab in gastrointestinal cancers: Balancing efficacy against the risk of intestinal perforation.

Yan Xu, Xiao-Bing Huang, Yong-Gang He

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yan XuDepartment of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital of Army Medical University, Chongqing 400037, China.
Xiao-Bing HuangDepartment of Hepatobiliary Medicine, The Second Affiliated Hospital of Army Medical University, Chongqing 400037, China.
Yong-Gang HeDepartment of Hepatobiliary Medicine, The Second Affiliated Hospital of Army Medical University, Chongqing 400037, China. xqyyhyg@tmmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The combination of radiotherapy with bevacizumab represents a promising therapeutic strategy for advanced gastrointestinal cancers. While this combination leverages synergistic mechanisms to enhance antitumor efficacy, it also poses significant safety concerns, particularly regarding the risk of intestinal perforation. This letter discusses the current understanding of this dual effect and underscores the importance of careful patient selection, advanced radiotherapy techniques, and vigilant toxicity monitoring to optimize clinical outcomes.

Indexed as

BevacizumabCombination therapyGastrointestinal cancersIntestinal perforationRadiotherapyToxicity management

Identifiers

PMID41640710
PMCPMC12865535

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.